ATE273700T1 - Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren - Google Patents

Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren

Info

Publication number: ATE273700T1
Authority: AT; Austria
Prior art keywords: virus; replication; inhibiting; dideoxydenucleotide; new method
Prior art date: 1993-05-21

Application number

AT94918016T

Other languages

English (en)

Inventor

Franco Lori

Andrea Cara

Wen-Yi Gao

Robert C Gallo

Original Assignee

Us Gov Health & Human Serv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-05-21

Filing date

1994-05-17

Publication date

2004-09-15

1994-05-17 Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv

2004-09-15 Application granted granted Critical

2004-09-15 Publication of ATE273700T1 publication Critical patent/ATE273700T1/de

Links

230000010076 replication Effects 0.000 title abstract 3
230000002401 inhibitory effect Effects 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
230000015572 biosynthetic process Effects 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
238000003786 synthesis reaction Methods 0.000 title 1
241000700605 Viruses Species 0.000 abstract 3
102100034343 Integrase Human genes 0.000 abstract 2
108010092799 RNA-directed DNA polymerase Proteins 0.000 abstract 2
210000004027 cell Anatomy 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
239000005549 deoxyribonucleoside Substances 0.000 abstract 2
230000001419 dependent effect Effects 0.000 abstract 2
VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 abstract 1
229910019142 PO4 Inorganic materials 0.000 abstract 1
108020005202 Viral DNA Proteins 0.000 abstract 1
210000004102 animal cell Anatomy 0.000 abstract 1
229940079593 drug Drugs 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
229960001330 hydroxycarbamide Drugs 0.000 abstract 1
230000003834 intracellular effect Effects 0.000 abstract 1
238000004519 manufacturing process Methods 0.000 abstract 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
239000010452 phosphate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Virology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Saccharide Compounds (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

AT94918016T 1993-05-21 1994-05-17 Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren ATE273700T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US6581493A	1993-05-21	1993-05-21
PCT/US1994/005515 WO1994027590A1 (en)	1993-05-21	1994-05-17	New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis

Publications (1)

Publication Number	Publication Date
ATE273700T1 true ATE273700T1 (de)	2004-09-15

Family

ID=22065285

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT94918016T ATE273700T1 (de)	1993-05-21	1994-05-17	Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren

Country Status (8)

Country	Link
US (5)	US6046175A (de)
EP (1)	EP0706387B1 (de)
JP (2)	JP4117901B2 (de)
AT (1)	ATE273700T1 (de)
AU (1)	AU685128B2 (de)
CA (1)	CA2163456C (de)
DE (1)	DE69433953T2 (de)
WO (1)	WO1994027590A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5827727A (en)	1990-02-01	1998-10-27	Emory University	Method of resolution of 1,3-oxathiolane nucleoside enantiomers
SE9003151D0 (sv) *	1990-10-02	1990-10-02	Medivir Ab	Nucleoside derivatives
WO1993012782A1 (en)	1991-10-31	1993-07-08	Elford Howard L	Method of treating viral diseases
ATE273700T1 (de) *	1993-05-21	2004-09-15	Us Gov Health & Human Serv	Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
US5521161A (en) *	1993-12-20	1996-05-28	Compagnie De Developpment Aguettant S.A.	Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6093702A (en) *	1993-12-20	2000-07-25	The United States Of America As Represented By The Department Of Health And Human Services	Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US6391859B1 (en)	1995-01-27	2002-05-21	Emory University	[5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en)	1995-01-27	1997-12-30	Emory University	Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5705522A (en) *	1995-09-15	1998-01-06	Compagnie De Developpement Aguettant S.A.	Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
CA2189097A1 (en)	1995-11-15	1997-05-16	Pin-Fang Lin	Composition and method of treating retroviral infection
US5719132A (en) *	1996-06-27	1998-02-17	Bristol-Myers Squibb Company	Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US6686462B2 (en) *	1997-02-28	2004-02-03	The Regents Of The University Of California	Antiviral compounds and methods of administration
US6114312A (en) *	1997-03-07	2000-09-05	Research Institute For Genetic And Human Therapy (R.I.G.H.T.)	Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
US20020022034A1 (en) *	1997-09-15	2002-02-21	Julianna Lisziewicz	Therapeutic DNA vaccination
AU6761198A (en) *	1998-03-17	1999-10-11	Julianna Lisziwiewicz	Anti-hiv combination comprising hydroxyurea, ddi, and a protease inhibitor
US6251874B1 (en) *	1998-03-26	2001-06-26	Research Institute For Genetic And Human Therapy (R.I.G.H.T.)	Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo
WO2000045844A1 (en) *	1999-02-03	2000-08-10	Franco Lori	Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
US20050196765A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050158735A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of proliferating cell nuclear antigen (PCNA) gene expression using short interfering nucleic acid (siNA)
US20050176025A1 (en) *	2001-05-18	2005-08-11	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of B-cell CLL/Lymphoma-2 (BCL-2) gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) *	2001-05-18	2005-09-15	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) *	2001-05-18	2005-06-09	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
EP1572067A4 (de) *	2001-05-18	2009-05-13	Sirna Therapeutics Inc	Konjugate und zusammensetzungen für die zelluläre freisetzung
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) *	2001-05-18	2005-09-08	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050233997A1 (en) *	2001-05-18	2005-10-20	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050159381A1 (en) *	2001-05-18	2005-07-21	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of chromosome translocation gene expression using short interfering nucleic acid (siNA)
US9657294B2 (en)	2002-02-20	2017-05-23	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9181551B2 (en)	2002-02-20	2015-11-10	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
JP5046219B2 (ja)	2002-10-31	2012-10-10	リガンド・ファーマシューティカルズ・インコーポレイテッド	１，３−プロパン−１−アリールジオールの新規環状リン酸ジエステルおよびそのプロドラッグへの使用
CN101088557A (zh)	2006-06-12	2007-12-19	天津市扶素生物技术有限公司	用于预防或治疗hiv感染的药用组合物及其应用
KR101302802B1 (ko) *	2008-04-23	2013-09-02	라벤브릭 엘엘씨	반사성 및 열반사성 표면의 광택 조절
US20090317466A1 (en) *	2008-06-18	2009-12-24	Franco Lori	Fixed dose pharmaceutical composition comprising hyroxyurea and didanosine
US9011817B2 (en) *	2009-09-03	2015-04-21	The Board Of Trustees Of The Leland Stanford Junior University	Compounds and methods of making compounds
WO2012058210A1 (en)	2010-10-29	2012-05-03	Merck Sharp & Dohme Corp.	RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
JP2017512183A (ja)	2014-02-13	2017-05-18	リガンド・ファーマシューティカルズ・インコーポレイテッド	プロドラッグ化合物およびそれらの使用
CN106687118A (zh)	2014-07-02	2017-05-17	配体药物公司	前药化合物及其用途
WO2018187479A1 (en) *	2017-04-04	2018-10-11	Case Western Reserve University	Method of modulating ribonucleotide reductase
RU2020126177A (ru)	2018-01-09	2022-02-10	Лиганд Фармасьютикалз, Инк.	Ацетальные соединения и их терапевтическое применение
GB202111184D0 (en) *	2021-08-03	2021-09-15	Hendriks Gerardus Johannes	Methods

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8324800D0 (en) *	1983-09-15	1983-10-19	Pasteur Institut	Antigens
ATE108794T1 (de) *	1985-05-15	1994-08-15	Wellcome Found	Therapeutische nucleoside und deren herstellung.
WO1987001284A1 (en) *	1985-08-26	1987-03-12	United States Of America, Represented By The Unite	Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
IL77496A (en) *	1986-01-01	1989-02-28	Univ Ramot	Anti-viral preparations comprising isatine 3-thiosemicarbazones
US5110600A (en) *	1988-01-25	1992-05-05	The Regents Of The University Of California	Method of treating viral infections with amino acid analogs
US5026687A (en) *	1990-01-03	1991-06-25	The United States Of America As Represented By The Department Of Health And Human Services	Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
DK0558673T3 (da) *	1990-11-19	1996-07-29	Monsanto Co	Retrovirale proteaseinhibitorer
WO1993012782A1 (en) *	1991-10-31	1993-07-08	Elford Howard L	Method of treating viral diseases
US5300059A (en) *	1991-11-19	1994-04-05	Hydro Slip Technologies Inc.	Bloodbag and method of making same
WO1993023368A1 (en) *	1992-05-20	1993-11-25	G.D. Searle & Co.	Urea-containing hydroxyethylamine compounds as retroviral protease inhibitors
ATE273700T1 (de) *	1993-05-21	2004-09-15	Us Gov Health & Human Serv	Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
US6093702A (en)	1993-12-20	2000-07-25	The United States Of America As Represented By The Department Of Health And Human Services	Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
US5521161A (en) *	1993-12-20	1996-05-28	Compagnie De Developpment Aguettant S.A.	Method of treating HIV in humans by administration of ddI and hydroxycarbamide

1994
- 1994-05-17 AT AT94918016T patent/ATE273700T1/de not_active IP Right Cessation
- 1994-05-17 JP JP51846694A patent/JP4117901B2/ja not_active Expired - Fee Related
- 1994-05-17 US US08/245,259 patent/US6046175A/en not_active Expired - Fee Related
- 1994-05-17 DE DE69433953T patent/DE69433953T2/de not_active Expired - Lifetime
- 1994-05-17 CA CA002163456A patent/CA2163456C/en not_active Expired - Fee Related
- 1994-05-17 WO PCT/US1994/005515 patent/WO1994027590A1/en not_active Ceased
- 1994-05-17 AU AU69519/94A patent/AU685128B2/en not_active Ceased
- 1994-05-17 EP EP94918016A patent/EP0706387B1/de not_active Expired - Lifetime
2000
- 2000-02-03 US US09/497,700 patent/US6194390B1/en not_active Expired - Fee Related
2001
- 2001-01-08 US US09/756,411 patent/US20010008905A1/en not_active Abandoned
2005
- 2005-10-14 US US11/250,899 patent/US20060052317A1/en not_active Abandoned
- 2005-12-27 JP JP2005375358A patent/JP2006143743A/ja active Pending
2006
- 2006-03-08 US US11/371,116 patent/US20060154892A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JPH08509957A (ja)	1996-10-22
AU685128B2 (en)	1998-01-15
US6194390B1 (en)	2001-02-27
EP0706387A1 (de)	1996-04-17
WO1994027590A1 (en)	1994-12-08
US20060052317A1 (en)	2006-03-09
CA2163456C (en)	2009-06-23
EP0706387B1 (de)	2004-08-18
US6046175A (en)	2000-04-04
US20010008905A1 (en)	2001-07-19
US20060154892A1 (en)	2006-07-13
DE69433953D1 (de)	2004-09-23
JP4117901B2 (ja)	2008-07-16
CA2163456A1 (en)	1994-12-08
JP2006143743A (ja)	2006-06-08
DE69433953T2 (de)	2005-08-25
AU6951994A (en)	1994-12-20

Legal Events

Date	Code	Title	Description
2005-02-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE273700T1 (de)	2004-09-15	Neues verfahen zur hemmung der replication der virus - abhängigen reverse transciptase durch verwendung von dideoxydenucleotide-synthese inhibitoren
ES2101358T3 (es)	1997-07-01	Inhibicion de la produccion de tnf.
DE3888425D1 (de)	1994-04-21	Virale Expressionsinhibitoren.
DE69533264D1 (de)	2004-08-19	Inhibitoren der il-6 aktivitaet
EA200401540A1 (ru)	2005-06-30	Спироиндолинпиперидиновые производные
DE60019904D1 (de)	2005-06-09	Verwendung von sulfamat derivaten zur behandlung von impulsiven störungen
RU99103643A (ru)	2000-12-20	Тиолсульфонамидные ингибиторы металлопротеазы
DE69633227D1 (de)	2004-09-30	Systematische evoultion von liganden durch exponentielle anreicherung: gewebe-selex
WO2006130688A3 (en)	2007-08-09	Compounds for inhibiting cathepsin activity
DK0705244T3 (da)	1999-07-19	Nitrato-aminosyredisulfid til behandling af sygdomme i det cardiovaskulære system
ATE401079T1 (de)	2008-08-15	Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen
ATE403635T1 (de)	2008-08-15	Verbindungen zur unterdrückung der hiv-tat- transaktivierung
EP0254461A3 (de)	1990-06-13	Bekämpfung von Pflanzennematoden mittels substituierten Hydrazone
DK461881A (da)	1982-04-21	Fremgangsmaade til fremstilling af 2-phenylalkylpyrrolidin- eller- piperidin-forbindelser eller syreadditionssalte deraf
Collins et al.	1963	Growth regulators and flowering: III. Antimetabolites
DK0759973T3 (da)	2002-01-21	Fremgangsmåde til klaring af vinase
EP0193770A3 (de)	1987-05-13	Neue Derivate von 3,4,5-Trihydroxypiperidin, Verfahren zu ihrer Herstellung und ihre Verwendung
DE69832051D1 (de)	2005-12-01	Aktivierte iod-verbindungen zur behandlung von krebs und aids
Harris et al.	1984	The effects of ethanol, valinomycin and cycloheximide on the endogenous circa‐tidal rhythm of the estuarine amphipod Corophium volutator (Pallas)
DK1380639T3 (da)	2009-12-21	Fremgangsmåde til fremstilling af en vandig-alkoholisk oplösning
ATE213231T1 (de)	2002-02-15	Michellamine zur verwendung als antivirale wirkstoffe, zusammensetzung und behandlungsverfahren
DE50302546D1 (de)	2006-04-27	Verfahren zur herstellung von transgenen pflanzen mit erhöhter virusresistenz durch "silencing" pflanzlicher dnaj-ähnlicher proteine
DK160310C (da)	1991-07-29	Analogifremgangsmaade til fremstilling af 6-oe(cyclisk amino)ethylaminoaatetrahydrotriazolooe3,4-aaaphthalaziner eller farmaceutisk acceptable syreadditionssalte deraf
DE69130266D1 (de)	1998-11-05	Optisch wirksame Alkylendioxybenzolderivate und ihre Verwendung als Arzneimittel
BR0115097A (pt)	2003-12-30	Composto, e, método para a formação do mesmo